FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A
FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A
Ultragenyx Pharmaceutical
RARE $14.46 USD
Biopharmaceutical company
Company Info
Recent News
Ultragenyx Trial Failure Revives Debate About How to Treat a Rare Neuro Disorder
Article from MedCity News about Ultragenyx Trial Failure Revives Debate About How to Treat a Rare Neuro Disorder.
Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decision
Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decision
Ultragenyx, after FDA speed bump, lands 1st gene therapy nod
Ultragenyx, after FDA speed bump, lands 1st gene therapy nod
Ultragenyx Gene Therapy Becomes First FDA-Approved Treatment for Ultra-Rare Disease
Ultragenyx Gene Therapy Becomes First FDA-Approved Treatment for Ultra-Rare Disease